MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study

MS disease activity in RESTORE: A randomized 24-week natalizumab treatment interruption study

Bibliographic Details
Main Authors:	Fox, Robert J., Cree, Bruce A.C., De Sèze, Jerome, Gold, Ralf, Hartung, Hans-Peter, Jeffery, Douglas, Kappos, Ludwig, Kaufman, Michael, Montalbán, Xavier, Weinstock-Guttman, Bianca, Anderson, Britt, Natarajan, Amy, Ticho, Barry, Duda, Petra
Format:	Online
Language:	English
Published:	Lippincott Williams & Wilkins 2014
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4011468/

Similar Items

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS
by: Kappos, Ludwig, et al.
Published: (2015)

Natalizumab in the pediatric MS population: results of the Italian registry
by: Ghezzi, Angelo, et al.
Published: (2015)

Is There Extra Cost of Institutional Care for MS Patients?
by: Noyes, Katia, et al.
Published: (2013)

Clinical effects of natalizumab on multiple sclerosis appear early in treatment course
by: Kappos, Ludwig, et al.
Published: (2013)

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results
by: Butzkueven, Helmut, et al.
Published: (2014)

Outcome and survival of asymptomatic PML in natalizumab-treated MS patients
by: Dong-Si, Tuan, et al.
Published: (2014)

Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab
by: Antoniol, Caroline, et al.
Published: (2015)

Natalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two Italian MS Centers
by: Lo Re, Marianna, et al.
Published: (2015)

Anti–JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy
by: Plavina, Tatiana, et al.
Published: (2014)

Natalizumab-related anaphylactoid reactions in MS patients are associated with HLA class II alleles
by: de la Hera, Belén, et al.
Published: (2014)

Natalizumab treatment of multiple sclerosis in Spain: results of an extensive observational study
by: Fernández, O., et al.
Published: (2012)

Comparative efficacy of switching to natalizumab in active multiple sclerosis
by: Spelman, Timothy, et al.
Published: (2015)

Risk Acceptance in Multiple Sclerosis Patients on Natalizumab Treatment
by: Tur, Carmen, et al.
Published: (2013)

Unraveling Natalizumab Effects on Deregulated miR-17 Expression in CD4+ T Cells of Patients with Relapsing-Remitting Multiple Sclerosis
by: Meira, Maria, et al.
Published: (2014)

Natalizumab in the treatment of Crohn’s disease
by: Guagnozzi, Danila, et al.
Published: (2008)

Natalizumab in the treatment of multiple sclerosis
by: Brown, Brandon A
Published: (2009)

Molecular mechanism underlying the impact of vitamin D on disease activity of MS
by: Munger, Kassandra L, et al.
Published: (2014)

Efficacy and Side Effects of Natalizumab Therapy in Patients with Multiple Sclerosis
by: Hoepner, Robert, et al.
Published: (2014)

Humoral response to EBV is associated with cortical atrophy and lesion burden in patients with MS
by: Zivadinov, Robert, et al.
Published: (2016)

Changes in JC Virus-Specific T Cell Responses during Natalizumab Treatment and in Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
by: Perkins, Molly R., et al.
Published: (2012)

Natalizumab-induced POU2AF1/Spi-B upregulation: A possible route for PML development
by: Meira, Maria, et al.
Published: (2016)

Natalizumab for the treatment of relapsing multiple sclerosis
by: Rudick, Richard A, et al.
Published: (2008)

Pulmonary eosinophilia associated to treatment with natalizumab
by: Curto, Elena, et al.
Published: (2016)

Natalizumab alters the TCR repertoire after one year of treatment in four MS patients
by: Michel, Laure, et al.
Published: (2011)

A link between long-term natalizumab dosing in MS and PML: Putting the puzzle together
by: Major, Eugene O., et al.
Published: (2016)

Natalizumab Therapy Modulates miR-155, miR-26a and Proinflammatory Cytokine Expression in MS Patients
by: Mameli, Giuseppe, et al.
Published: (2016)

7T MRI in natalizumab-associated PML and ongoing MS disease activity: A case study
by: Sinnecker, Tim, et al.
Published: (2015)

CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients
by: Lieberman, Linda A., et al.
Published: (2016)

Natalizumab Significantly Improves Cognitive Impairment over Three Years in MS: Pattern of Disability Progression and Preliminary MRI Findings
by: Mattioli, Flavia, et al.
Published: (2015)

Rising JCV-Ab index during natalizumab therapy for MS: Inauspicious for a highly efficacious drug
by: Javed, Adil, et al.
Published: (2016)

Divergent Trends of Anti-JCPyV Serum Reactivity and Neutralizing Activity in Multiple Sclerosis (MS) Patients during Treatment with Natalizumab
by: Diotti, Roberta Antonia, et al.
Published: (2016)

Iron deposition and inflammation in multiple sclerosis. Which one comes first?
by: Zivadinov, Robert, et al.
Published: (2011)

Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study
by: Barbin, Laetitia, et al.
Published: (2016)

Lipocalin 2 is present in the EAE brain and is modulated by natalizumab
by: Marques, Fernanda, et al.
Published: (2012)

The discovery of natalizumab, a potent therapeutic for multiple sclerosis
by: Steinman, Lawrence
Published: (2012)

Natalizumab in Crohn's disease: past and future areas of applicability
by: Armuzzi, Alessandro, et al.
Published: (2013)

The TOUCH program and natalizumab: Fundamental flaw in patient protection
by: Avasarala, Jagannadha
Published: (2016)

Incomplete Susac syndrome exacerbated after natalizumab
by: Zhovtis Ryerson, Lana, et al.
Published: (2015)

CD4 cell response to interval therapy with natalizumab
by: Berkovich, Regina, et al.
Published: (2015)

Compensability index for compensation radiotherapy after treatment interruptions
by: Putora, Paul Martin, et al.
Published: (2012)